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Abstract
Objective
Coronavirus disease 2019 (COVID-19) is associated with diffuse lung injury that can progress to acute
respiratory distress syndrome, multisystem-organ failure, and death. The inflammatory storm seen in many
COVID-19 patients closely resembles secondary hemophagocytic lymphohistiocytosis (sHLH) which has
been described in other virus-associated severe sepsis. We sought to describe the incidence of sHLH in
COVID-19 infected patients.
Design
In this retrospective study, we reviewed the records of critically ill COVID-19 positive patients to determine
the incidence of sHLH. An H-score for sHLH diagnosis was determined for each study participant, with a
score greater than 169 points needed for diagnosis.
Setting
A quaternary referral center in suburban Pennsylvania, USA.
Patients
All study participants had a positive COVID-19 test, and were deemed critically ill defined as receiving
invasive mechanical ventilation and/or who expired.
Measurements and Main Results
Of the 246 records identified, 242 records met inclusion criteria and were reviewed. Eighty five patients were
excluded from analysis due to missing H-score data parameters. Overall, 32 of 157 (20.38%, 95% CI:14.38-
27.54%) patients met diagnostic criteria for sHLH. The average age was 69.42 years (standard deviation (SD)
14.81). Patients diagnosed with sHLH were more likely to be younger (61.09 years vs 69.38 years, P = 0.0036),
male (71.88% vs 52.00%, P = 0.0433), and require mechanical ventilation (96.88% vs 72.80%, P = 0.0035).
Conclusions
Among critically ill COVID-19 positive patients, the incidence of sHLH is higher than previously reported in
patients with non-COVID-19 related sepsis. Clinicians caring for COVID-19 patients should consider this
secondary diagnosis and subsequent appropriate treatments, especially in those requiring mechanical
ventilation.
Categories: Internal Medicine, Infectious Disease, Pulmonology
Keywords: covid-19, sars-cov-2 (severe acute respiratory syndrome coronavirus -2), severe respiratory distress
syndrome, adult respiratory distress syndrome, multi-viral pneumonia, retrospective studies, incidence and prognosis
Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019
(COVID-19), is a novel beta coronavirus that emerged from a zoonotic source in Wuhan, China in 2019 [1].
COVID-19 can present in a wide spectrum of clinical symptoms; the majority of COVID-19 cases are
asymptomatic or present with a mild viral prodrome of fever, cough, dyspnea, and myalgias [2]. Some
patients progress to viral pneumonia requiring hospitalization. A relatively small percentage of patients
progress to acute respiratory distress syndrome, multisystem-organ failure, and death [3,4].
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In many of very severe cases, evidence of cytokine storm has been demonstrated through increased acute-
phase reactants and inflammatory modulators. Significant elevation of ferritin, Interleukin (IL) 6, C-reactive
protein, IL-1, Granulocyte-macrophage colony stimulating factor (GMCSF), and tumor necrosis factor-alpha
(TNF-α) can be seen [3]. Immunosuppressive therapy with glucocorticoids has been shown to provide
benefit in severely ill patients with COVID-19 disease [4]. Mehta et al. proposed that the clinical profile of
COVID-19 patients closely resembled that of sHLH, with hyperferritinemia, hypertriglyceridemia,
cytopenias, fever, organomegaly, transaminitis, hypofibrinogenemia, and high IL-6 [5].
Secondary hemophagocytic lymphohistiocytosis is a syndrome that results from defective hyperactivation of
natural killer and cytotoxic T-cells that can lead to multi-organ failure similar to what some patients have
been experiencing with COVID-19 infection [6,7]. Secondary hemophagocytic lymphohistiocytosis has many
known triggers including neoplasm, autoimmune, and infection, with the most common infectious cause
being viral [7]. In septic patients, the incidence of sHLH has been estimated between 3.7 and 4.3% [7].
Prompt treatment of sHLH with broad immunosuppressive or immunomodulatory therapies such as
glucocorticoids, cyclosporine, intravenous gamma globulin, anti-IL-6 and anti-IL-1 agents, or
chemotherapeutics is important for favorable outcomes. However, use of immunosuppressant therapy in
COVID-19 patients must be done cautiously, as co-infections can occur with COVID-19, and such infections
have been associated with severity of SARS-CoV-2 as well as poor outcomes [8]. 
SHLH can be diagnosed by calculating an “H-score” consisting of multiple data points. The H-score
generates a probability for the presence of sHLH, and according to Fardet et al., a score greater than 169
points is 93% sensitive and 86% specific for sHLH [9]. While the presence of bone marrow hemophagocytosis
on aspirate is also a criterion in the H-score, it is not mandatory for a diagnosis and is often not practical to
obtain in critically ill patients [6].
While the role of cytokine storm in the pathogenesis of some severe COVID-19 infections has been
discussed within the literature, to our knowledge, the incidence of sHLH in these patients has not been
determined. Here we present a retrospective review to determine the incidence of sHLH in critically ill,
COVID-19 positive patients at a single institution in northeastern Pennsylvania, USA.
Materials And Methods
We retrospectively reviewed the records of 246 critically ill, COVID-19 positive patients to determine the
incidence of sHLH. We defined critically ill as any patient requiring invasive mechanical ventilation and/or
who expired. Patients were identified using an internal COVID-19 registry automatically populated by a
positive test. Laboratory work, medical history, vital signs, and imaging (computed tomography (CT) scan
and/or ultrasound) were reviewed to calculate an H-score for as many study participants as possible. 
Patients had to meet the following inclusion criteria: admission to our hospital network between March 15th
and June 15th, 2020, positive COVID-19 test upon or during admission, age ≥ 18 years, having received
invasive mechanical ventilatory support related to COVID-19 infection and/or death attributed to COVID-19
infection. We further excluded any COVID-19 positive patient with baseline cytopenia (defined as platelets ≤
110,000 per mm3, white blood cell ≤5.0 g/dL, and/or hemoglobin ≤ 9.2 g/dL).
We identified 246 patients, and 242 met all entry criteria. Three of the four excluded had one or more
baseline cytopenia and the remaining patient underwent invasive mechanical ventilation for a surgical
procedure rather than for respiratory support related to COVID-19 infection. 
All data were obtained by a single reviewer from patients’ electronic medical records. We collected data on
temperature, presence or absence of hepatomegaly and splenomegaly, triglycerides, fibrinogen, ferritin,
serum aspartate aminotransferase, presence/absence of immune suppression (defined as known Human
Immunodeficiency Virus (HIV) infection or those receiving long-term immunosuppression therapy), date of
admission and discharge, age, ethnicity, sex, blood type, hospital, and Intensive Care Unit (ICU) length of
stay (LOS), ventilator days, and discharge disposition. No study participant underwent bone marrow aspirate
testing. Study data were collected and managed using REDCap electronic data capture tools hosted at Lehigh
Valley Health Network. REDCap (Research Electronic Data Capture) is a secure, web-based software platform
designed to support data capture for research studies, providing 1) an intuitive interface for validated data
capture; 2) audit trails for tracking data manipulation and export procedures; 3) automated export
procedures for seamless data downloads to common statistical packages; and 4) procedures for data
integration and interoperability with external sources [10,11]. Lehigh Valley Health Network's Institutional
Review Board approved Study 00000670 on 7/23/2020. 
Descriptive statistics were generated for all variables collected. The mean was presented with the standard
deviation for normally distributed continuous variables. Categorical variables were presented as frequencies
and percentages. Variables were then compared between groups. The chi-square test of independence was
used for categorical variables unless > 20% of the expected cell counts were < 5 in which case the Fisher’s
exact test was used instead. The independent samples t-test was used for continuous variables; however, if
the data in either group was not normally distributed the Mann-Whitney U test was used instead. The
2021 Allen et al. Cureus 13(7): e16735. DOI 10.7759/cureus.16735 2 of 9
incidence of sHLH was calculated excluding those who did not have sufficient data to accurately determine
H-score. The confidence limits around the incidence were calculated using the exact binomial method. All
statistical tests were two-tailed and a P-value <0.05 was considered statistically significant. The data
analysis for this paper was generated using SAS software, Version 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Of the 246 records identified, 242 were reviewed (Table 1). Eighty-five patients were excluded from the sHLH
incidence calculation due to a lack of data to determine the presence or absence of sHLH. Specifically, those
for whom the sum of the maximum value of the missing H-score parameters could potentially raise the score
above the 169-point cutoff. The average age was 69.42 years (standard deviation (SD) 14.80). One hundred
forty-two patients were male (58.68%) and 100 were female (41.32%). Most patients were white (62.40%)
followed by other (31.40%), black (3.31%), and Asian/Pacific Islander (2.89%). Patients diagnosed with sHLH
were more likely to be younger (61.09 years vs 69.48 years, P = 0.0036) and male (71.88% vs 52.00%, P =
0.0433). We found no statistically significant association between sHLH and race (P = 0.8860). 
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 Entire Sample (n=242) sHLH (n=32) No sHLH (n=125) Missing Parameters (n=85) P-valuea
Age mean±SD 69.42±14.81 61.09±14.65 69.38±14 72.61±14.96 0.0036b
Gender n(%)     0.0433c
     Male 142 (58.68) 23 (71.88) 65 (52) 54 (63.53)  
     Female 100 (41.32) 9 (28.13) 60 (48) 31 (36.47)  
Race n(%)     0.8860d
     White 151 (62.40) 20 (62.50) 75 (60) 56 (65.88)  
     Black 8 (3.31) 1 (3.13) 4 (3.20) 3 (3.53)  
     Asian/Pacific Islander 7 (2.89) 2 (6.25) 5 (4) 0  
     Other 76 (31.40) 9 (28.13) 41 (32.80) 26 (30.59)  
Blood Type n(%)e     0.6207d
     A- 5 (3.79) 0 3 (4.11) 2 (5.88)  
     B- 4 (3.03) 1 (4) 2 (2.74) 1 (2.94)  
     A+ 43 (32.58) 6 (24) 24 (32.88) 13 (38.24)  
     B+ 10 (7.58) 2 (8) 7 (9.59) 1 (2.94)  
     AB- - - - -  
     AB+ 3 (2.27) 2 (8) 1 (1.37) 0  
     O+ 60 (45.45) 13 (52) 32 (43.84) 15 (44.12)  
     O- 7 (5.30) 1 (4) 4 (5.48) 2 (5.88)  
TABLE 1: Demographics
Abbreviations: sHLH = secondary Hemophagocytic Lymphohistiocytosis, SD = Standard Deviation.
Notes: Numbers presented in the table were calculated for column totals. The cut-point for sHLH was an H-score of >169. Some patients were
missing parameters used to calculate H-Score. If the sum of the maximum value of the missing parameters could have potentially pushed the
patient over the cut-point for sHLH their final H-score was marked invalid and the presence of sHLH could not be determined (these patients are
represented in the second to last column in the table).
a. P-values were computed for the comparison between those with and without sHLH, those shown in bold are statistically significant.
b. Calculated using the independent samples t-test.
c. Calculated using the chi-square test.
d. Calculated using Fisher’s exact test.
e. 110 records were missing data for blood type so n=132.
A total of 157 patients had sufficient data to calculate an H-score, and among them, the incidence of sHLH








Immunosuppression n(%)b     0.6967c
     Yes 14 (5.86) 3 (9.38) 8 (6.40) 3 (3.66)  
     No 225 (94.14) 29 (90.63) 117 (93.60) 79 (96.34)  
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Temp (°F) n(%)     <0.0001e
     < 101.1 95 (39.26) 1 (3.13) 60 (48) 34 (40)  
     101.1-102.9 93 (38.43) 11 (34.38) 50 (40) 32 (37.65)  
     >102.9 54 (22.31) 20 (62.50) 15 (12) 19 (22.35)  
Organomegaly n(%)f     <0.0001c
     No 80 (68.97) 6 (25) 51 (75) 23 (95.83)  
     Hepat OR Splen 31 (26.72) 15 (62.50) 16 (23.53) 0  
     Hepat AND Splen 5 (4.31) 3 (12.50) 1 (1.47) 1 (4.17)  
Hemoglobin median (IQR)g 9 (7.80-12.10) 7.55 (7-8.30) 8.80 (7.70-11.70) 11.20 (8.80-12.85) 0.0003d
Anemia n(%)g     0.0137e
     Yes 127 (52.70) 26 (81.25) 72 (57.60) 29 (34.52)  
     No 114 (47.30) 6 (18.75) 53 (42.40) 55 (65.48)  
Platelets (#/L) median (IQR)g 167 (102-253) 123 (85-170) 173 (102-262) 195.50 (117-273.50) 0.0072d
Thrombocytopenia n(%)g     0.1390e
     Yes 64 (26.56) 13 (40.63) 34 (27.20) 17 (20.24)  
     No 177 (73.44) 19 (59.38) 91 (72.80) 67 (79.76)  
Leukopenia (g/dL) median
(IQR)g
6.70 (4.30-12) 4.75 (3.85-6.70) 6.70 (4.30-10.40) 8.50 (5.15-13.60) 0.0351d
Leukopenia n(%)g     0.0012e
     Yes 75 (31.12) 19 (59.38) 36 (28.80) 20 (23.81)  
     No 166 (68.88) 13 (40.63) 89 (71.20) 64 (76.19)  
Cytopenia n(%)h     0.0043e
     1 lineage 82 (49.70) 8 (26.67) 58 (61.05) 16 (40)  
     2 lineages 66 (40) 16 (53.33) 28 (29.47) 22 (55)  
     3 lineages 17 (10.30) 6 (20) 9 (9.47) 2 (5)  
Ferritin (ng/mL) n(%)i     <0.0001e
     < 2,000 138 (64.79) 2 (6.25) 102 (83.61) 34 (57.63)  
     2,000-6,000 53 (24.88) 18 (56.25) 17 (13.93) 18 (30.51)  
     > 6,000 22 (10.33) 12 (37.50) 3 (2.46) 7 (11.86)  
Triglyceride (mg/dL) n(%)j     <0.0001e
     < 150 42 (24.42) 0 39 (35.78) 3 (9.68)  
     150-400 88 (51.16) 13 (40.63) 60 (55.05) 15 (48.39)  
     > 400 42 (24.42) 19 (59.38) 10 (9.17) 13 (41.94)  
Fibrinogen (mg/dL) n(%)k     0.3605c
     ≤ 250 9 (5.96) 3 (11.11) 5 (4.81) 1 (5)  
     > 250 142 (94.04) 24 (88.89) 99 (95.19) 19 (95)  
AST (U/L) n(%)g     0.5826c
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     < 30 9 (3.73) 0 4 (3.20) 5 (5.95)  
     ≥ 30 232 (96.27) 32 (100) 121 (96.80) 79 (94.05)  
Final H-Score median (IQR)l 107 (52-160) 190 (183.50-195) 87 (43-119) - <0.0001d
TABLE 2: H-score Parameters
Abbreviations: sHLH = secondary Hemophagocytic Lymphohistiocytosis, SD = Standard Deviation, Temp = temperature, Hepat = Hepatomegaly,
Splen = Splenomegaly, and AST = Serum Glutamic Oxaloacetic Transaminase.
Notes: Numbers presented in the tables were calculated for column totals. The cut-point for sHLH was an H-score of >169. Median and Interquartile
range (IQR) are presented for temperature, hemoglobin, platelets, leukopenia, and H-score because the data was significantly skewed for at least
one of the groups. The cut-point for anemia was hemoglobin of ≤ 9.2 (g/dL). Cut-point for thrombocytopenia was a platelet count of ≤ 110 (#/L). The
cut-point for leukopenia was a white blood cell count ≤ 5.0 (g/dL). Some patients were missing parameters used to calculate H-score. If the sum of
the maximum value of the missing parameters could have potentially pushed the patient over the cut-point for sHLH their final H-score was marked
invalid and the presence of sHLH could not be determined (these patients are represented in the second to last column in the table). 
a. P-values were computed for the comparison between those with and without sHLH, those shown in bold are statistically significant.
b. Three records were missing for immunosuppression so n=239.
c. Calculated using Fisher’s exact test.
d. Calculated using the Mann-Whitney U test.
e. Calculated using the chi-square test.
f. 126 records were missing for organomegaly so n=116.
g. One record was missing for hemoglobin/anemia, platelets/thrombocytopenia, leukopenia, and AST so n=241 for those variables.
h. 77 records were missing for cytopenia so n=165.
i. 29 records were missing for ferritin so n=213.
j. 70 records were missing for triglyceride so n=172.
k. 91 records were missing for fibrinogen so n =151.
l. Due to missing parameters H-score was unable to be calculated for 85 records so n for H-score is 157.
We found no significant difference between sHLH and non-sHLH patients in relation to hospital LOS (18 vs
15 days, P = 0.0704), ICU LOS (16 vs 14 days, P = 0.2053), ventilator days (14 vs 13 days, P = 0.2761), or
discharge disposition (P = 0.5159) (Table 3). Patients with sHLH were significantly more likely to require
mechanical ventilation (96.88% vs 72.80%, P = 0.0035).
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 Entire Sample (n=242) sHLH (n=32) No sHLH (n=125) Missing Parameters (n=85) P-valuea
LOS median(IQR) 12 (5-23) 18 (8.50-35.50) 15 (6-24) 6 (2-15) 0.0704b
ICU LOS median (IQR)c 12 (6-20) 16 (8.50-29.50) 14 (8-20) 8 (5-16) 0.2053b
Vent n(%)     0.0035d
     Yes 167 (69.01) 31 (96.88) 91 (72.80) 45 (52.94)  
     No 75 (30.99) 1 (3.13) 34 (27.20) 40 (47.06)  
Vent Days median(IQR)e 12 (6-20) 14 (8-30) 13 (6-21) 8 (5-15) 0.2761b
DC Dispo n(%)     0.5159f
     Deceased 167 (69.01) 19 (59.38) 83 (66.40) 65 (76.47)  
     Rehab/SNF 70 (28.93) 13 (40.63) 39 (31.20) 18 (21.18)  
     Home 5 (2.07) 0 3 (2.40) 2 (2.35)  
TABLE 3: Hospitalization Information
Abbreviations: sHLH = secondary Hemophagocytic Lymphohistiocytosis, LOS = Length of Stay, IQR = Interquartile Range, ICU = Intensive Care
Unit, Vent = ventilator, DC = discharge, Dispo = disposition, Rehab/SNF = Rehabilitation/Skilled Nursing Facility.
Notes: Numbers presented in the table were calculated for column totals. Cut-point for sHLH was a H-score of >169. Median and IQR are presented
for LOS, ICU LOS, and Vent Days because the data was significantly skewed to the right. Some patients were missing parameters used to calculate
H-Score. If the sum of the maximum value of the missing parameters could have potentially pushed the patient over the cut-point for sHLH their
final H-Score was marked invalid and presence of sHLH could not be determined (these patients are represented in the second to last column in the
table).
a. P-values were computed for the comparison between those with and without sHLH, those shown in bold are statistically significant.
b. Calculated using the Mann-Whitney U test.
c. N for ICU LOS is 198 because other 44 patients were not admitted to ICU during hospitalization.
d. Calculated using the chi-square test.
e. N for vent days is 167 because the other 75 patients were not on a vent during hospitalization
f. Calculated using the Fisher’s exact test.
Discussion
Our study suggests the incidence of sHLH in critically ill, COVID-19 patients is higher than previously cited
in the literature for non-COVID-19 related sepsis [7]. Our sHLH patients were significantly younger
suggesting profound hyperinflammation requires a functional immune system. Inflammation is an essential
part of the immune response, but in patients with COVID-19, there is an excessive and prolonged cytokine
storm, leading to acute respiratory distress syndrome, multiple-organ failure, and death [12]. Thirty-one of
the thirty-two patients diagnosed with sHLH underwent mechanical ventilation during admission. The
remaining patient was not mechanically ventilated in keeping with their pre-existing advanced directive.
To more accurately reflect true incidence, we included patients with missing data in our analysis if the sum
of the maximum value of the missing H-score parameters were unable to eclipse the 169-point threshold. 
The mainstay of sHLH treatment is immunosuppression, and the recently published RECOVERY trial
demonstrated improved outcomes for COVID-19 patients receiving dexamethasone with the greatest
benefit in mechanically ventilated patients [9]. Eight patients with H-scores between 160-169 points all
underwent mechanical ventilation. We believe these patients would have benefitted from
immunosuppression despite not meeting the sHLH diagnostic threshold. Additionally, of the 85 patients
with missing data excluded from incidence analysis, five would have surpassed the 169-point threshold with
either the presence of hepatomegaly or splenomegaly. Five other patients would have met diagnostic criteria
if they had both organomegalies. We believe this information demonstrates that the incidence in our study
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is likely underestimated and underscores the importance of considering immunosuppressive treatment in
patients with a reactive hemophagocytic-like syndrome despite not meeting a true sHLH diagnosis. 
Our study had several limitations. A single researcher reviewed data retrospectively from one institution.
Most of our study participants were white, raising concerns with external validity. Many patients had
missing data, limiting our ability to calculate accurate H-scores for all participants. 
We attributed absent data to several factors. Some blood testing (namely triglyceride, fibrinogen, and ferritin
levels) were not routinely obtained at our institution early in the pandemic. Our health network limited
imaging for infection control purposes, and we could not comment on the presence/absence of
organomegaly in many patients. Finally, no patient underwent bone marrow biopsy due to feasibility in
critical illness. Other researchers have questioned the use of the H-score for this reason; the condition of
patients with COVID-19 may not permit bone marrow examination, which can make it difficult to
demonstrate hemophagocytosis [13]. Furthermore, some researchers recommend against using the H-score
due to a possible lack of sensitivity; while hyperferritinemia is associated with sHLH, in severe COVID-19
patients, the ferritin concentrations often do not reach the required threshold of 2000·0 ng/mL until much
later in the disease, thus limiting early intervention [14]. Expeditious management of the cytokine storm in
the early stage is critical for improving treatment and reducing the mortality rate of COVID-19 patients [12].
In summary, among critically ill, COVID-19 positive patients, the incidence of sHLH is higher than
previously reported in sepsis literature. Our COVID-19 positive critically ill sHLH patients were significantly
younger suggesting profound hyperinflammation requires a functional immune system. Clinicians caring for
COVID-19 patients should consider this secondary diagnosis and appropriate treatments. They should
especially review this for COVID-19 positive patients requiring mechanical ventilation.
Conclusions
In summary, among critically ill COVID-19 positive patients, the incidence of sHLH is higher than previously
reported in sepsis literature. Our COVID-19 positive critically ill sHLH patients were significantly younger
suggesting profound hyperinflammation requires a functional immune system. Clinicians caring for COVID-
19 patients should consider this secondary diagnosis and appropriate treatments. They should especially
review this for COVID-19 positive patients requiring mechanical ventilation.
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